The nation of Zimbabwe has turned down a significant US healthcare agreement worth $367m (£272m) over five years because of Washington's demand for confidential biological samples.
This rejection was revealed following a internal memorandum from December was leaked, which showed Head of State Emmerson Mnangagwa believed the arrangement was "unbalanced".
An official spokesman later stated that the United States was seeking biological samples for scientific study and profit but was unwilling to share the resulting advantages from any future medical innovations.
"We are forced to start the challenging and unfortunate process of scaling back our health aid in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the US had provided more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has called for further negotiations to secure a agreement acceptable to all parties so the country's vital HIV treatment initiative can continue.
Wider Background
Zimbabwe's decision follows a comparable situation in neighbouring Kenya, where a court suspended a related health funding agreement following legal challenges were raised about the safety of citizens' health data.
Since returning to the presidency recently, US President Donald Trump has reduced overseas assistance and closed the US Agency for International Development (USAID).
The agency had administered assistance for the US government, but Trump claimed its spending was "wasteful" and his administration was pursuing government-to-government deals to enhance transparency and accountability.
Based on statements, Sixteen nations in Africa have so far agreed to similar health pacts, constituting more than $18.3bn in committed funds.
Specifics of the Rejected Deal
The money for Zimbabwe would have funded "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this partnership might have yielded extraordinary benefits for Zimbabwean communities, especially the 1.2 million presently on antiretroviral therapy via American-funded programmes," Tremont commented.
However, official spokesman Nick Mangwana argued the arrangement was "unequal".
"The proposal required Zimbabwe to share its genetic material and health information for a long time, with no corresponding guarantee of benefiting from any medical innovations – like new medicines or tests – that might be developed from that provided information," Mangwana explained.
"In essence, our nation would supply the raw materials for scientific discovery without any certainty that the resulting innovations would be available to our citizens should a new pandemic emerge."
National Interest and International Frameworks
He also noted that the American exit from the World Health Organization (WHO) and its push of bilateral deals were undermining systems already set up via the international organization.
Mangwana gave as an example its Pandemic Benefit-Sharing scheme created to manage future pandemics.
"This framework is intended to ensure that when a country provides its information, the benefits – such as medicines and cures – are distributed fairly, not commercialised solely by those with the resources to create them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as anti-American sentiment," he added.
"We encourage ongoing discussions with our US partners on how future collaboration might be structured in a way that respects the sovereignty and dignity of each country."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it acknowledged the official position, but suggested that talks need to persist since a large portion of the country's Aids initiatives relied on international support.
"Where specific concerns arise, such as those relating to information security or implementation frameworks, these can frequently be resolved through technical clarification and negotiated safeguards," it commented.
The situation underscores the complex debate between receiving crucial foreign assistance and safeguarding a country's data in an increasingly data-driven world.